Founders

Phialogics business idea is the result of a long and successful collaboration between A. Ernst, P. Oromi, M. Parnham, A. Weigert and A. v. Knethen. Each founding partner has a unique skill set with experience in industry and R&D that complement each other.

Andreas Ernst, acting CEO, CSO
Andreas Ernst, acting CEO, CSO

International expert in generating affinity reagents with training from the labs of A. Skerra, A. Plückthun and S. Sidhu. With stints at Genentech, the University of Toronto, Medical Faculty of the Goethe University and the Fraunhofer IME-TMP, he has a 20+ years experience in running protein engineering projects in multinational teams.

Pascal Oromi, CBO
Hightech and Biotech industry veteran with more than 30 work experience at senior level. Part of management team at Gemalto that managed the M&A of SafeNet in 2014. In 2016, he left Gemalto at the position of Vice President Mobile Banking to become the managing director of Cenexi, a medical device CDMO and left this position in 2020 to apply his business expertise as advisor for start up companies.
Pascal Oromi, CBO
Michael J. Parnham
Michael J. Parnham
Senior research manager for 30 years in medium sized (Nattermann, PLIVA) and multinational companies (Rhone-Poulenc, GSK). Currently serves as CSO of EpiEndo Pharmaceuticals. He helped to bring 7 projects including biologicals to clinical trials, 3 to registration and/or market approval (Ebselen, Epoetal, G-CSF/Nivestim).
Andreas Weigert
15 years experience in inflammation and cancer research. As an author of more than 135 research papers in peer reviewed journals, he has an outstanding track record in animal and cutting-edge 3D in vitro disease models.
Andreas Weigert
Andreas von Knethen
Andreas von Knethen
25 years experience in pre-clinical murine disease models of acute inflammation. Since Jan 2020 head of Experimental Anesthesiology in the Department of Anesthesiology, Intensive Care Medicine and Pain Therapy at the University Hospital Frankfurt/Main

Advisors

Patrice Denèfle
Patrice Denèfle
Patrice currently serves as CSO of Centogene and acts as business adviser to Phialogics. Patrice is the former General Manager of Institut Roche (2015-2019) and was previsouly Senior Vice-President, Digital and Translational Sciences at IPSEN from 2010 to 2014. He has held several managerial positions within large corporations (Roche/Genentech, Sanofi-Aventis, Rhône-Poulenc Rorer, RPR Gencell) as well as biotech and mid-size pharmaceutical companies - both in France and the US. Patrice holds a Doctorate in Microbiology and an HDR in Molecular Pharmacology. He is qualified as a Professor in Molecular and Cellular Biology and was adjunct professor at Université Paris-Descartes and a lecturer at several elite schools for ParisTech. He also graduated from CEDEP-INSEAD.